Stanford researchers have developed a system that assesses altered mental states in both human and animal subjects using neural biomarkers, allowing for repeatable cross-species studies of potential treatments for psychiatric and neurological disorders.
Stanford researchers Robert Lowsky and Samuel Strober have developed a strategy for maintaining normal graft function without immune suppression medication. Kidney transplant recipients require lifelong use of immunosuppressants to minimize rejection risk.
Researchers at Stanford have developed methods and compositions to provide inducible production of anti-inflammatory cytokines in mesenchymal stem cells (MSCs).
Researchers at Stanford developed a novel technique to induce persistent mixed hematopoietic cell chimerism in organ recipients to protect against organ graft rejection and increase immune tolerance.
Stanford scientists have developed a plant-derived zinc protoporphyrin (ZnPP) produced from legume hemoglobin, a breakthrough therapy candidate for treating neonatal jaundice.
Stanford researchers have developed a novel blood-based diagnostic platform that leverages circulating bacteriophage DNA (phage cfDNA) to enable sensitive and highly specific detection of both overt and subclinical bacterial infections, while effectively discriminating them fr
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Researchers in the Wyss-Coray Lab are investigating a potential therapeutic antibody to treat lysosomal storage disorders and other related neurodegenerative diseases.
Stanford researchers have developed an innovative, non-invasive therapeutic strategy to treat myocardial fibrosis (MF), a key driver of arrhythmia and heart failure in LMNA-related dilated cardiomyopathy (LMNA-DCM).
Stanford researchers in the Cochran Lab have patented a potential pancreatic cancer therapeutic approach using novel agents that bind tightly to and inhibit a cancer factor called LIF (leukemia inhibitory factor).
Stanford researchers have developed a novel RNA-targeting therapeutic platform using CRISPR-Cas13d to selectively degrade oncogenic mRNA associated with uveal melanoma (UM), an aggressive and treatment-resistant form of eye cancer.
SARS-CoV2 is known to gain entry into epithelial cells through the association of its viral spike protein with the ACE2 receptor, which is widely expressed on epithelial cell types.
Stanford researchers developed an electrochemical reactor process that combines electrodialysis and membrane stripping, reduces the chemical inputs needed and expands recovered product portfolio to alkaline ammonia (for cleaning products) in ratios customized to a user's speci
Stanford researchers have developed an Electrodialysis and Nitrate Reduction Process (EDNR) that produces high-purity ammonia from agricultural runoff.
Stanford researchers have developed an "electrocatalyst-in-a-box" that extracts wastewater nitrate and converts it into ammonia. Nitrogen pollution threatens water security and human health, and demand for ammonia continues to grow.